Deficiency or inhibition of CXCR2, the main chemokine receptor recruiting MDSCs to TME, reduces the infiltration of CD11b+Ly6Ghigh MDSCs to TME, leading to enhanced anti-tumor effects upon treatment with checkpoint inhibitor [181]. The gene discussed is CXCR2; the disease is neoplasm.